Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kallyope
Biotech
Kallyope links oral obesity combo to 3% weight loss at Week 13
Kallyope slipped out results from a phase 2 obesity trial, linking the oral combination to weight loss of 2.9% after 13 weeks of treatment.
Nick Paul Taylor
Feb 27, 2025 10:17am
Biotech's top money raisers: 2022
Apr 11, 2023 9:19am
Catalent shakes up leadership, taps new CEO—Chutes & Ladders
Jul 8, 2022 9:30am
New report surveys declining biopharma deal activity in Q1
Jun 9, 2022 4:56am
Kallyope delays IPO to snag $236M series D for 22 programs
Feb 15, 2022 8:00am
Former Merck exec joins Kallyope as president, soon-to-be CEO
Aug 5, 2021 11:56am
